OakChart

eXoZymes Inc

EXOZHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

4.00-0.04 (-0.99%)
2026-11-12 03:22 CET
Market cap
37.13 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-10.19 USD m
Free cash flow, TTM
-7.14 USD m
EPS diluted, TTM
-1.20
P/E
-
Compare

Price

EXOZ against its 20, 50 and 200-day averages
2050200
4.006.008.0010.0026K53KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26EXOZclose 4.0020-day 4.1250-day 5.23200-day 7.494.0052w low

78.3% under the 52-week high of 18.40 on 10 Nov 2025. 52-week low 3.24 on 27 Oct 2026. Last 15 sessions, 50.9% high to low

Volume 1.03× normal · the line is the 50-bar volume average

Profile

EXOZ
52-week range, 5% of the way up
3.2417.57

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

Employees32
IPONov 13, 2024
Beta3.30
ATR, 14d0.53
Rel volume1.03
Short float0.56%
Insider own65.52%
Inst own1.26%

Snapshot

6 groups

Valuation

Index-
Market Cap37.13M
Enterprise Value32.57M
Income-10.19M
Sales0.00M
Book/sh0.39
Cash/sh0.61
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees32
IPONov 13, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B10.16
P/C6.57
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio3.81
Current Ratio3.81
Debt/Eq0.30
LT Debt/Eq0.20
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.20
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y-110.59% -74.96%
Sales past 3/5Y- -
EPS Y/Y TTM-21.64%
Sales Y/Y TTM-
EPS Q/Q-17.96%
Sales Q/Q-
EarningsAug 20 AMC
EPS/Sales Surpr.- -

Ownership

Insider Own65.52%
Insider Trans-0.05%
Inst Own1.26%
Inst Trans0.47%
ROA-115.42%
ROE-187.16%
ROIC-231.85%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-2.97%
SMA50-23.54%
SMA200-46.61%
Trades-

Technical

Shs Outstand9.28M
Shs Float3.20M
Short Float0.56%
Short Ratio1.96
Short Interest0.02M
52W High17.57 -77.23%
52W Low3.24 23.46%
Volatility12.31% 15.27%
ATR (14)0.53
RSI (14)39.73
Beta3.30
Rel Volume1.03
Avg Volume9.13K
Volume9,409

Performance

Perf Week-7.19%
Perf Month-12.85%
Perf Quarter-33.33%
Perf Half Y-59.51%
Perf YTD-63.30%
Perf Year-73.65%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom-
Target Price-
Prev Close4.04
Price4.00
Change %-0.99%

Peers

Mkt cap
TickerCompanyMkt cap
CDXSCodexis Inc106.93M
DNAGinkgo Bioworks Holdings Inc679.14M
TWSTTwist Bioscience Corp8.07B
ABSIAbsci Corp1.74B
CBUSCibus Inc88.66M
GEVOGevo Inc449.97M
LOOPLoop Industries Inc11.60M
AMTXAemetis Inc104.90M
ALTOAlto Ingredients Inc297.88M
FFFuturefuel Corp123.25M

Insider trading

5 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Perriman Damien AlanChief Commercial OfficerOct 12 '26Sale5.213,72919,42728,692Oct 26 03:01 PM
Heltzen MichaelChief Executive OfficerAug 26 '26Buy7.485053,77514,708Sep 02 07:33 PM
Heltzen MichaelChief Executive OfficerAug 25 '26Buy7.513502,63014,203Sep 02 07:33 PM
Korman Tyler PazChief Scientific OfficerApr 09 '26Sale10.537507,894729,123Apr 10 04:30 PM
Korman Tyler PazChief Scientific OfficerApr 08 '26Sale10.047507,530729,873Apr 10 04:30 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 108
  • eXoZymes CEO to Discuss Commercialization, Key Milestones, and Potential Catalysts in Fireside Chat with Water Tower Research (ACCESSWIRE)
  • eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT (ACCESSWIRE) -7.88%
  • EXoZymes Inc (EXOZ) (Q2 2026) Earnings Call Highlights: Strategic Pivot and 10x Productivity ... (GuruFocus.com)
  • eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today (ACCESSWIRE) +10.00%
  • eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets (ACCESSWIRE) +5.97%
  • MDB Capital Holdings LLC (MDBH) (Q2 2026) Earnings Call Highlights: Strategic Pivots and Asset ... (GuruFocus.com)
  • eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026 (ACCESSWIRE) +10.77%
  • eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing (ACCESSWIRE) -8.38%
  • eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery (ACCESSWIRE) -7.27%
  • eXoZymes Inc. Announces Closing of $6 Million Public Offering (ACCESSWIRE) -14.69% +23.70%
  • eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants (ACCESSWIRE) -7.71%
  • eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program (ACCESSWIRE) -5.12%
  • eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast (ACCESSWIRE)
  • MDB Capital Holdings LLC (MDBH) Q4 2025 Earnings Call Highlights: Strategic Innovations and ... (GuruFocus.com) +14.99%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
No quarterly earnings.

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual-0.117-0.117-0.244-0.701-1.093-1.2017
Period20212022202320242025TTM
EPS, quarterly-0.163-0.265-0.219-0.222-0.282-0.273-0.316-0.28-0.332
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual000.07000
Period20212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual11.34112.58.3688.3688.4079.281
Period20212022202320242025MRQ
Shares, quarterly8.3686.2528.3688.3688.3878.3878.4078.4799.281
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue0.000.000.000.070.000.00
Cost of Goods Sold Incl. D&A0.300.290.270.200.150.06
Gross Profit-0.30-0.29-0.27-0.13-0.15-0.06
Selling, General and Administrative Excl. Other10.269.435.661.671.181.23
Research and Development4.893.711.870.530.350.45
Other Operating Expense0.000.000.000.000.000.00
Operating Income-10.56-9.72-5.93-1.80-1.33-1.29
Interest Expense---0.000.000.00
Unusual Expense-0.170.008E-060.200.00-0.08
Net Income Before Taxes-10.30-9.26-5.86-2.00-1.33-1.21
Income Taxes-0.11-0.110.000.040.060.00
Consolidated Net Income-10.19-9.16-5.86-2.04-1.40-1.21
Net Income From Continuing Operations-10.19-9.16-5.86-2.04-1.40-1.21
Net Income-10.19-9.16-5.86-2.04-1.40-1.21
EPS (Recurring)-1.19-1.09-0.70-0.23-0.12-0.12
EPS (Basic, Before Extraordinaries)-1.20-1.09-0.70-0.24-0.12-0.12
EPS (Diluted)-1.20-1.09-0.70-0.24-0.12-0.12
EBITDA-10.26-9.43-5.66-1.60-1.18-1.23
Non-Operating Income (Expense)0.090.450.070.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense2.381.301.130.220.170.20
Gross Margin----181.06--
Operating Margin----2,563.50--
Net Margin----2,909.12--
Shares Outstanding9.288.418.378.3712.5011.34
Market Capitalization37.1337.1393.31---

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.080.070.070.070.070.070.070.07
Gross Profit-0.08-0.07-0.07-0.07-0.07-0.07-0.07-0.07
Selling, General and Administrative Excl. Other2.882.312.622.452.481.881.921.54
Research and Development1.441.121.111.220.800.580.630.72
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.95-2.39-2.70-2.52-2.55-1.95-1.98-1.61
Interest Expense-----0.00-0.04
Unusual Expense-0.170.000.000.000.000.008E-060.00
Net Income Before Taxes-2.88-2.37-2.76-2.29-2.36-1.86-1.84-1.66
Income Taxes0.000.00-0.110.000.000.00-0.000.00
Consolidated Net Income-2.88-2.37-2.66-2.29-2.36-1.86-1.84-1.66
Net Income From Continuing Operations-2.88-2.37-2.66-2.29-2.36-1.86-1.84-1.66
Net Income-2.88-2.37-2.66-2.29-2.36-1.86-1.84-1.66
EPS (Recurring)-0.35-0.28-0.32-0.27-0.28-0.22-0.22-0.26
EPS (Basic, Before Extraordinaries)-0.33-0.28-0.32-0.27-0.28-0.22-0.22-0.26
EPS (Diluted)-0.33-0.28-0.32-0.27-0.28-0.22-0.22-0.26
EBITDA-2.88-2.31-2.62-2.45-2.48-1.88-1.92-1.54
Non-Operating Income (Expense)-0.100.02-0.060.240.190.090.150.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.220.500.240.430.240.320.250.32
Shares Outstanding9.288.488.418.398.398.378.376.25
Market Capitalization37.1362.9991.42121.0182.6784.9381.19-

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments3.049.720.070.560.55
Short Term Receivables0.520.740.880.810.47
Inventories0.000.000.000.000.00
Other Current Assets0.380.360.260.100.03
Total Current Assets3.9410.821.211.471.05
Net Property, Plant & Equipment1.932.212.341.221.30
Total Investments and Advances0.000.000.000.000.00
Intangible Assets-0.000.000.000.00
Other Assets0.110.000.000.000.00
Total Assets5.9713.033.562.692.35
Short Term Debt Incl. Current Port. of LT Debt0.330.230.220.150.13
Accounts Payable1.240.920.700.000.00
Income Tax Payable-0.000.040.060.00
Other Current Liabilities0.010.181.450.430.27
Total Current Liabilities1.571.332.420.630.40
Long Term Debt0.921.161.390.460.59
Provision for Risks Charges0.000.000.000.000.00
Other Liabilities0.090.120.140.210.16
Total Liabilities2.572.613.941.311.15
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00
Common Equity3.4010.42-0.381.371.20
Total Shareholders Equity3.4010.42-0.381.371.20
Accumulated Minority Interest0.000.000.000.000.00
Total Equity3.4010.42-0.381.371.20
Total Liabilities & Stockholders Equity5.9713.033.562.692.35
Book Value Per Share0.401.25-0.050.110.11
Tangible Book Value Per Share0.401.25-0.050.110.11
Full-Time Employees323129--
Price to Book Ratio10.1617.36---
Return on Assets-96.38-70.65-65.29-55.49-
Return on Equity-132.56-116.80-412.54-108.66-
Return on Invested Capital-212.29-50.63-203.33-76.03-67.77
Quick Ratio2.518.120.502.322.61
Current Ratio2.518.120.502.322.61

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-10.19-9.16-5.86-2.04-1.40-1.21
Depreciation0.300.290.270.200.150.06
Other Funds (Non Cash)2.631.991.110.440.180.10
Funds from Operations-7.26-6.88-4.49-1.40-1.07-1.05
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.270.38-4.020.22-0.19-0.54
Income Taxes Payable-0.00-0.04-0.020.06-
Cash from Operating Activities-7.00-6.50-8.51-1.18-1.26-1.59
Capital Expenditures-0.15-0.17-0.40-0.29-0.19-0.42
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.00-0.020.000.00
Other Sources0.000.020.040.000.100.11
Cash from Investing Activities-0.15-0.15-0.36-0.31-0.09-0.31
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock5.860.0014.540.001.362.31
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock5.860.0014.540.001.362.31
Proceedsfrom Stock Options0.000.0014.530.001.362.31
Issuance or Reduction of Debt, Net-0.05-0.033.980.800.000.00
Change in Long Term Debt-0.05-0.030.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.05-0.030.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.200.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities5.81-0.0318.521.001.362.31
Net Change in Cash-1.33-6.689.65-0.490.010.41
Free Cash Flow-7.14-6.67-8.90-1.47-1.44-2.01
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments5.651.443.045.106.998.51
Short Term Receivables0.220.300.520.300.260.60
Inventories0.000.000.000.000.000.00
Other Current Assets0.300.340.380.200.290.31
Total Current Assets6.172.093.945.617.539.42
Net Property, Plant & Equipment1.711.821.932.012.152.11
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets----0.000.00
Other Assets0.110.110.110.110.000.00
Total Assets7.984.025.977.729.6811.53
Short Term Debt Incl. Current Port. of LT Debt0.340.330.330.320.290.24
Accounts Payable1.271.231.240.900.931.07
Other Current Liabilities-0.000.010.010.020.000.14
Total Current Liabilities1.621.581.571.241.221.44
Long Term Debt0.740.830.921.001.111.09
Provision for Risks Charges1.900.000.000.000.000.00
Other Liabilities0.070.080.090.100.120.11
Total Liabilities4.332.492.572.342.442.64
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity3.651.533.405.377.248.88
Total Shareholders Equity3.651.533.405.377.248.88
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity3.651.533.405.377.248.88
Total Liabilities & Stockholders Equity7.984.025.977.729.6811.53
Book Value Per Share0.390.180.400.640.861.06
Tangible Book Value Per Share0.390.180.400.640.861.06
Full-Time Employees--32---
Price to Book Ratio10.1618.5817.0116.729.318.39
Return on Assets-115.42-124.45-96.38-147.87--
Return on Equity-187.16-185.84-132.56-940.69--
Return on Invested Capital-65.49-100.52-61.54-35.86-28.29-18.62
Quick Ratio3.811.322.514.536.196.52
Current Ratio3.811.322.514.536.196.52

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-2.88-2.37-2.66-2.29-2.36-1.86
Depreciation0.080.070.070.070.070.07
Other Funds (Non Cash)1.010.510.680.440.560.31
Funds from Operations-1.80-1.79-1.90-1.78-1.73-1.47
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.160.26-0.07-0.080.190.34
Income Taxes Payable----0.000.00
Cash from Operating Activities-1.64-1.52-1.97-1.86-1.54-1.13
Capital Expenditures1E-06-0.06-0.07-0.01-0.05-0.03
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.00-2E-062E-060.020.00
Cash from Investing Activities1E-06-0.06-0.07-0.01-0.03-0.03
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock5.860.000.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock5.860.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-0.01-0.01-0.01-0.020.04-0.04
Change in Long Term Debt-0.01-0.01-0.01-0.020.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.01-0.01-0.01-0.020.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities5.85-0.01-0.01-0.020.04-0.04
Net Change in Cash4.21-1.59-2.06-1.89-1.53-1.21
Free Cash Flow-1.64-1.58-2.05-1.87-1.59-1.16

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.56%0.0M3.2M8.45K
2026-10-150.55%0.0M3.2M7.33K
2026-09-300.58%0.0M3.2M8.88K
2026-09-150.68%0.0M3.0M9.15K
2026-08-310.73%0.0M3.0M9.29K
2026-08-140.64%0.0M3.1M9.30K
2026-07-310.75%0.0M2.9M8.86K
2026-07-150.67%0.0M2.9M7.97K
2026-06-300.63%0.0M2.5M6.57K
2026-06-150.65%0.0M2.3M5.42K
2026-05-290.69%0.0M2.2M4.73K
2026-05-150.55%0.0M2.2M4.46K
2026-04-300.60%0.0M2.1M4.41K
2026-04-150.55%0.0M2.1M4.62K
2026-03-310.50%0.0M2.1M3.45K
2026-03-130.46%0.0M2.1M3.87K
2026-02-270.46%0.0M2.1M3.73K
2026-02-130.50%0.0M2.1M3.66K
2026-01-300.47%0.0M2.1M3.94K
2026-01-150.47%0.0M2.1M3.45K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-09FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-11-06S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-10-264Statement of changes in beneficial ownership of securities2026-10-09SEC
2026-10-214/A2026-08-19SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-098-KCurrent report2026-10-09SEC
2026-09-28DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-28DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-13SEC
2026-09-188-KCurrent report2026-09-17SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-018-KCurrent report2026-06-30SEC
2026-06-30424B5SEC
2026-06-268-KCurrent report2026-06-25SEC
2026-06-178-KCurrent report2026-06-17SEC
2026-06-088-KCurrent report2026-06-05SEC
2026-06-08424B5SEC
2026-06-04424B5SEC
2026-05-29424B5SEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-04-108-KCurrent report2026-04-10SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100019.43K1
2026-090000
2026-086.41K200
2026-070000
2026-060000
2026-050000
2026-040015.42K2
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC0.61%
GEODE CAPITAL MANAGEMENT, LLC0.25%
Davidson Kahn Capital Management, LLC0.19%
BlackRock, Inc.0.11%
VANGUARD FIDUCIARY TRUST CO0.10%
MORGAN STANLEY0.01%
Tower Research Capital LLC0.00%
UBS Group AG0.00%
BARCLAYS PLC0.00%
Caitong International Asset Management Co., Ltd0.00%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND0.29%
VANGUARD EXTENDED MARKET INDEX FUND0.25%
Fidelity Extended Market Index Fund0.13%
iShares Micro-Cap ETF0.10%
Fidelity Series Total Market Index Fund0.03%
Fidelity Total Market Index Fund0.02%
Fidelity Nasdaq Composite Index Fund0.02%
1290 VT Micro Cap Portfolio0.00%
Victory Extended Market Index Fund0.00%

OakChart. EXOZ. Cached 15 minutes.

Some panels did not load: ratings.